Welcome to The Visible Embryo

Home-- -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs in Pregnancy- -- Pregnancy Calculator- --Female Reproductive System- -Contact

Welcome to The Visible Embryo, a comprehensive educational resource on human development from conception to birth.

The Visible Embryo provides visual references for changes in fetal development throughout pregnancy and can be navigated via fetal development or maternal changes.

The National Institutes of Child Health and Human Development awarded Phase I and Phase II Small Business Innovative Research Grants to develop The Visible Embryo. Initally designed to evaluate the internet as a teaching tool for first year medical students, The Visible Embryo is linked to over 600 educational institutions and is viewed by more than one million visitors each month.

Today, The Visible Embryo is linked to over 600 educational institutions and is viewed by more than 1 million visitors each month. The field of early embryology has grown to include the identification of the stem cell as not only critical to organogenesis in the embryo, but equally critical to organ function and repair in the adult human. The identification and understanding of genetic malfunction, inflammatory responses, and the progression in chronic disease, begins with a grounding in primary cellular and systemic functions manifested in the study of the early embryo.

WHO International Clinical Trials Registry Platform


The World Health Organization (WHO) has created a new Web site to help researchers, doctors and
patients obtain reliable information on high-quality clinical trials. Now you can go to one website and search all registers to identify clinical trial research underway around the world!



Home

History

Bibliography

Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System

Contact The Visible Embryo

News Alerts Archive

Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.
Content protected under a Creative Commons License.

No dirivative works may be made or used for commercial purposes.

Return To Top Of Page
Pregnancy Timeline by SemestersFetal liver is producing blood cellsHead may position into pelvisBrain convolutions beginFull TermWhite fat begins to be madeWhite fat begins to be madeHead may position into pelvisImmune system beginningImmune system beginningPeriod of rapid brain growthBrain convolutions beginLungs begin to produce surfactantSensory brain waves begin to activateSensory brain waves begin to activateInner Ear Bones HardenBone marrow starts making blood cellsBone marrow starts making blood cellsBrown fat surrounds lymphatic systemFetal sexual organs visibleFinger and toe prints appearFinger and toe prints appearHeartbeat can be detectedHeartbeat can be detectedBasic Brain Structure in PlaceThe Appearance of SomitesFirst Detectable Brain WavesA Four Chambered HeartBeginning Cerebral HemispheresFemale Reproductive SystemEnd of Embryonic PeriodEnd of Embryonic PeriodFirst Thin Layer of Skin AppearsThird TrimesterSecond TrimesterFirst TrimesterFertilizationDevelopmental Timeline
Click weeks 0 - 40 and follow fetal growth
Google Search artcles published since 2007
 
Home-- -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs- Pregnancy Calculator- --Reproductive System-- News --Contact
 

April 25, 2013--------News Archive

 
Early identification of juvenile idiopathic arthritis
.

 






WHO Child Growth Charts
     

 

 

 

New genetic links to juvenile arthritis

Researchers have increased the number of confirmed genes linked to juvenile idiopathic arthritis (JIA) from three to 17 – a finding that will clarify how JIA fits into the spectrum of autoimmune disorders and help identify potential treatment targets.

Published April 21in Nature Genetics, the study involves an international research team that analyzed 2,816 JIA cases recruited from more than 40 pediatric rheumatology clinics. It was the largest collaborative patient population of JIA to date, including patient DNA samples from across the United States, Germany and United Kingdom. Susan Thompson, PhD, and researcher in the Division of Rheumatology at Cincinnati Children's Hospital Medical Center leads the study.

"These findings will help us understand how the long suspected genetic contributions to JIA are driving the disease process, with the ultimate goal being earlier and improved diagnosis and treatment," Thompson said.


JIA is the most common rheumatic disease of childhood that involves several different but related forms. Affecting some 50,000 children in the US, the actual cause of the disease remains unknown. JIA is considered an autoimmune disorder, in which the body's immune system mounts an attack against its own healthy tissues. JIA can be treated with medications and physical therapy, but the disease can persist for many patients into adulthood.


Prior to the current study, only three genes were associated with known JIA risk though scientists suspected the likelihood of more gene involvement. The research team used what is known as the Immunochip array to measure variation in the genes (DNA) coding for components of the immune system for 2,816 JIA patients in the study. Those findings were compared to the DNA of 13,000 healthy controls to look for genetic differences.

The analyses re-confirmed JIA's connection to the original three genes, identified a link to the 14 new genes and pointed to the possibility that another 11 genetic regions may be implicated. The scientists stressed that their work continues in order to identify additional genetic links, and recently began conducting functional studies to pinpoint disease processes.


Although the current study substantially increases the number of confirmed susceptibility genes for JIA, researcher data indicates that additional genetic risk factors still remain to be discovered.


Other researchers helping lead the study included Carl Langefeld, PhD, and Miranda Marion, MA, at the Wake Forest School of Medicine, Drs. Wendy Thomson, Anne Hinks and Joanna Cobb at the University of Manchester in the UK, and Sampath Prahalad, MD, at the Emory University School of Medicine.

Funding support for the research came, in part, from the U.S. National Institutes of Health (RC1-AR-058587, U01-AI-067 150S1, N01-AR-42272, P01-AR-048929, P30-AR-473639, K23-AR-50177, R01-AR-060893, R01-AR-057106, N01-AR-62277, P30-GM-103510, U19-AI-082714, P30-AR-053483, RP-PG-0310-1002, RC2AR059092, DK062431, DK62422, DK062432, DK06423, DK062429) from the Arthritis Foundation, The Val A. Browning Charitable Trust and the Marcus Foundation.

About Cincinnati Children's
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S. News and World Report's 2012 Best Children's Hospitals ranking. It is ranked #1 for neonatology and in the top 10 for all pediatric specialties. Cincinnati Children's is one of the top two recipients of pediatric research grants from the National Institutes of Health and a research affiliate of the University of Cincinnati College of Medicine. It is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at http://www.cincinnatichildrens.org.

Original article: http://www.eurekalert.org/pub_releases/2013-04/cchm-isf042413.php